Sanofi SA (SAN.FR) said Monday that it will acquire all outstanding shares in Bioverativ Inc. BIVV, +61.10% for $11.6 billion to expand its presence in specialty care and strengthening leadership in rare diseases. The operation is expected to close within three months, Sanofi said. The French company said that it will pay $105 in cash for each share. This price represents a 64% premium to Bioverativ's closing price on Jan. 19, the company said. U.S.-based Bioverativ, which generated $847 million in sales in 2016, is a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, Sanofi said.via